Exelixis Prepares for Zanza Launch Amid Slower-than-Expected NET Growth
Exelixis is preparing for the potential late-year launch of zanzalintinib (zanza) in third-line colorectal cancer, a market it estimates at $1.5 billion. The company remains focused on expanding CABOMETYX's presence in renal cell carcinoma and neuroendocrine tumors (NET), aiming to build toward a $3 billion franchise by 2027–2029. However, the rollout of CABOMETYX for NET has been slower than anticipated due to the disease’s indolent nature, which results in less frequent treatment decisions. Exelixis reported capturing about 47% new-patient market share in NET and views this as a positive indicator despite current adoption delays. The company expects generic competition on January 1, 2031 but does not see near-term threats from 505(b)(2) competitors like Handa Pharmaceuticals. Capital allocation remains focused on R&D, business development, and share repurchases under its $600 million buyback authorization.
Tickers: $EXEL
Topics: CABOMETYX colorectal cancer neuroendocrine tumors renal cell carcinoma zanzalintinib (zanza)